ライフサイエンスコーパス: proatherogenic

1 OX-2 expression in COX-1(-/-) macrophages is proatherogenic.

2 te, there is no in vivo evidence that CRP is proatherogenic.

3 induced by NFkappaB might be antirather than proatherogenic.

4 dhesion and proliferation and may thereby be proatherogenic.

5 d with a focus on those that are potentially proatherogenic.

6 at cholesteryl ester transfer protein can be proatherogenic.

7 tivity (cholesteryl ester transfer [CET]) is proatherogenic.

8 usality, and it has been claimed that CRP is proatherogenic.

9 rosis, whereas Cdkn2a appears to be modestly proatherogenic.

10 OSEs are immunogenic, proinflammatory, and proatherogenic.

11 e continued to dissect the potential diverse proatherogenic actions of C-reactive protein on cultured

12 may contribute to vasomotor dysfunction and proatherogenic actions of CRP, respectively.

13 her substrate deficiency plays a role in the proatherogenic actions of iNOS, we administered L-argini

14 oliferation of contractile cells, which have proatherogenic actions.

15 s to develop PPARgamma ligands that separate proatherogenic activities from antidiabetic and antiathe

16 s of LDL (glycation and oxidation), monocyte proatherogenic activity, and circulating levels of solub

17 /ApoA-I ratio, which reflects the balance of proatherogenic and antiatherogenic lipoproteins, is a ri

18 yroid hormones have been linked with various proatherogenic and antiatherogenic processes.

19 identifying candidate genes associated with proatherogenic and inflammatory processes.

20 OSEs are immunogenic, proinflammatory, proatherogenic and plaque destabilizing and represent da

21 statins affect the nature of lesions in the proatherogenic and proinflammatory environment of low ES

22 These responses may have proatherogenic and protective effects.

23 l NO and prostacyclin (PGI2) contribute to a proatherogenic and prothrombotic state.

24 ltiple genes and pathways, some of which are proatherogenic and some are protective.

25 lated arsenicals, but not arsenobetaine, are proatherogenic and that As3MT is required for arsenic to

26 icular helper-germinal center B-cell axis is proatherogenic and that CD8(+) regulatory T cells contro

27 en together, our data suggest that IL-17A is proatherogenic and that it plays an important role in bo

28 hether methylated arsenic intermediates were proatherogenic and whether arsenic biotransformation by

29 we demonstrate that HL deficiency raises the proatherogenic apoB-containing lipoprotein levels in pla

30 olesterol, reflecting reduced levels of both proatherogenic apoB-containing lipoproteins as well as H

31 se and atherosclerosis in hyperlipidemic and proatherogenic ApoE(-/-) mice.

32 ed gene disruption and crossed them with the proatherogenic apolipoprotein E-deficient mice (apoE(-/-

33 Both proatherogenic as well as atheroprotective roles have be

34 Several proatherogenic biological effects have been attributed t

35 The combination of the broad gamut of proatherogenic biological responses triggered by ligatio

36 trated for the first time that inhibition of proatherogenic caspase-1 activation in ECs improves angi

37 (+) T cells have recently been proposed as a proatherogenic cell subset, their full scope of actions

38 failure, and decreased levels of circulating proatherogenic cells in mice fed an atherogenic diet.

39 ion increasing influx of proinflammatory and proatherogenic cellular and noncellular substances into

40 Myeloid cell activation in combination with proatherogenic changes allowing for increased monocyte r

41 ze, we determined if MCMV infection produces proatherogenic changes in aortic gene expression.

42 ution changes, insulin resistance, and other proatherogenic changes in serum lipid levels.

43 These findings suggest that proatherogenic changes in SVGs may commence early after

44 on in response to hyperglycemia brings about proatherogenic changes in vascular endothelial cell func

45 These proatherogenic changes of lipoproteins may contribute to

46 tary components results in the production of proatherogenic circulating factors that act through a me

47 CD36 can be protective even in more extreme proatherogenic circumstances.

48 ining nutrients can lead to formation of the proatherogenic compound TMAO.

49 dized LDL (OxLDL) is enriched with lysoPC, a proatherogenic compound.

50 Under proatherogenic conditions, nitric oxide production from

51 h Ldlr(-/-) mice and studied under different proatherogenic conditions.

52 -6 or IFN-gamma did not induce expression of proatherogenic cysteine proteinase cathepsins from vascu

53 results indicate for the first time that the proatherogenic cytokine IL-18 induces human coronary art

54 ated previously that the proinflammatory and proatherogenic cytokine interleukin-18 (IL-18) stimulate

55 GIP induces the expression of the proatherogenic cytokine osteopontin (OPN) in mouse arter

56 ctivated by IFN-gamma, a proinflammatory and proatherogenic cytokine that mediates its downstream eff

57 ired for macrophage migration in response to proatherogenic cytokines (monocyte chemotactic protein-1

58 hyperlipidemia increases serum levels of the proatherogenic cytokines monocyte chemotactic protein (M

59 mechanism for MPO-dependent generation of a proatherogenic dysfunctional form of HDL in vivo.

60 ainst the development of insulin resistance, proatherogenic dyslipidemia, and aortic atherogenesis in

61 event the development of insulin resistance, proatherogenic dyslipidemia, and atherogenesis.

62 The potential proatherogenic effect of Ang-1 is further supported by t

63 he 2 types of mice, which indicates that the proatherogenic effect of CRP-associated AT1-R overexpres

64 provide a solid explanation for the observed proatherogenic effect of HHcy.

65 nd provide insight into the mechanism of the proatherogenic effect of p21.

66 Another potentially important proatherogenic effect of prolonged ER stress is activati

67 resence of the isoprostane will still have a proatherogenic effect.

68 ear whether NK cells behave as protective or proatherogenic effectors.

69 mediated increases in inflammatory genes and proatherogenic effects in the vasculature are enhanced b

70 ata indicate that CD4(+) NKT cells can exert proatherogenic effects independent of other lymphocytes.

71 we provide experimental evidence that LPS's proatherogenic effects may at least in part reflect alte

72 surprising findings suggest the presence of proatherogenic effects of alcohol in young adults, espec

73 To test this hypothesis, we compared the proatherogenic effects of ambient particles of <0.18 mic

74 ude that ultrafine particles concentrate the proatherogenic effects of ambient PM and may constitute

75 ears to reciprocally modulate and reduce the proatherogenic effects of C. pneumoniae infection.

76 te infection may be necessary to prevent the proatherogenic effects of C. pneumoniae infection.

77 y the host, appear to be responsible for the proatherogenic effects of CMV.

78 Because several proatherogenic effects of CRP have been documented in en

79 iated biotransformation was required for the proatherogenic effects of inorganic arsenite.

80 cal antagonism of TP suppresses the vascular proatherogenic effects of iPF2alpha-III.

81 of TSP-4 variants that could account for the proatherogenic effects of the (P387)TSP-4 variant.

82 ate components of the Ath diet have distinct proatherogenic effects on gene expression and suggest a

83 DL but has a markedly altered metabolism and proatherogenic effects on vascular cells.

84 g, and the molecular mechanisms of potential proatherogenic effects remain to be determined.

85 hat B cells have contradictory protective or proatherogenic effects that are also subset and context

86 rosclerosis where Smad1/5 is responsible for proatherogenic effects, whereas Smad2/3 regulate atherop

87 of lipid metabolism, and toxic sterols with proatherogenic effects.

88 ons and could contribute to proinflammatory, proatherogenic effects.

89 enoproteins such as GPx-1 to contribute to a proatherogenic endothelial phenotype.

90 LXR primarily in macrophages responding to a proatherogenic environment.

91 e expression and vascular gene activation in proatherogenic environments, and is also a marker of man

92 Evidence suggests that ACAT2 is a proatherogenic enzyme that contributes cholesteryl ester

93 lipase A(2) (sPLA(2)) represents a family of proatherogenic enzymes that hydrolyze lipoprotein phosph

94 ave been previously shown to induce multiple proatherogenic events in endothelial cells and macrophag

95 oxidized LDL (ox-LDL) is implicated in many proatherogenic events, we hypothesized that ox-LDL would

96 ell formation and has been suggested to be a proatherogenic factor.

97 These findings demonstrate that proatherogenic factors promote the polarization and infl

98 selectively suppressed the production of key proatherogenic factors such as monocyte chemoattractant

99 However, the contribution of proatherogenic factors to autoimmunity remains unclear.

100 these cells was found to be up-regulated by proatherogenic factors, which enhanced inflammation and

101 eatinine is probably a marker for unmeasured proatherogenic factors.

102 e mechanistic insights, especially under the proatherogenic flow condition, remain largely unknown.

103 Given the current evidence that TLRs are proatherogenic, flow suppression of TLR2 expression may

104 t aldosterone activates endogenous EC MR and proatherogenic gene expression in clinically important h

105 otype with lower insulin resistance, reduced proatherogenic gene expression, and preserved vascular f

106 moattractant protein 1 and the expression of proatherogenic genes in peripheral blood mononuclear cel

107 d that IRE1 regulates the expression of many proatherogenic genes, including several important cytoki

108 tch on antiatherogenic genes, and switch off proatherogenic genes.

109 nd Lp(a) was strengthened in the presence of proatherogenic homocysteine and was blocked by plasminog

110 We also tested whether ATG use induces a proatherogenic immune status.

111 these studies demonstrate that NKT cells are proatherogenic in the absence of exogenous stimulation,

112 T lymphocyte responses promote proatherogenic inflammatory events, which are influenced

113 IL-17A plays a proatherogenic inflammatory role during atherogenesis by

114 this cell subset as a critical regulator of proatherogenic innate immune cell responses in atheroscl

115 These uncleared SMCs elicited a series of proatherogenic juxtacrine responses associated with incr

116 flows in the branches and curved regions are proatherogenic, laminar flows in the straight parts are

117 These results demonstrate that Adamts7 is proatherogenic, lending directionality to the original g

118 aldosterone stimulates transcription of the proatherogenic leukocyte-EC adhesion molecule intercellu

119 ow that macrophage deficiency of ABCA1/G1 is proatherogenic likely by promoting plaque inflammation a

120 Patients with CKD have major proatherogenic lipid abnormalities that are treatable wi

121 lesions in cx3cr1(-/-)apoE(-/-) mice; and 3) proatherogenic lipids (oxidized low density lipoprotein

122 Proatherogenic lipids increase pyroptosis significantly

123 Proatherogenic lipids induce higher caspase-1 activation

124 th each other (r=0.51, 95% CI 0.47-0.56) and proatherogenic lipids.

125 l1 establish another functional link between proatherogenic lipoproteins and platelet-mediated thromb

126 hese results provide a critical link between proatherogenic lipoproteins and their metabolic target,

127 ) plasma levels reflect the concentration of proatherogenic lipoproteins very low-density lipoprotein

128 n (PLTP) increases the circulating levels of proatherogenic lipoproteins, accelerates blood coagulati

129 genic high-density lipoproteins (HDL) to the proatherogenic low-density and very low-density lipoprot

130 vidence that molecular lipid determinants of proatherogenic macrophage phenotypes are present in larg

131 suggests thrombospondin-1 (TSP-1), a potent proatherogenic matricellular protein, as a putative link

132 However, the molecular details of this proatherogenic mechanism were not known.

133 novel pathway by which IFN-alpha serves as a proatherogenic mediator through repression of eNOS-depen

134 ase or production of the proinflammatory and proatherogenic mediators CD40 ligand (CD40L) and thrombo

135 stress markers, inhibited the expression of proatherogenic mediators, and blocked leukocyte-endothel

136 We determined the association of the proatherogenic metabolite trimethylamine N-oxide (TMAO)

137 s, the atherosclerotic lesion development in proatherogenic mice.

138 ther metabolic abnormalities, is part of the proatherogenic milieu, it is possible that insulin resis

139 Finally, we found that proatherogenic miR-33 can directly inhibit human OGG1 ex

140 stimulation of the MMP/TIMP balance of three proatherogenic MMPs and increased activities of two MAPK

141 ntion of LDL on cell surfaces may facilitate proatherogenic modifications and support an expanded rol

142 We used the natural prooxidant and proatherogenic molecule oxidized low-density lipoprotein

143 idence suggests that C-reactive protein is a proatherogenic molecule that plays an active role.

144 Trimethylene N-oxide (TMAO), a proatherogenic molecule, is produced from the metabolism

145 metric dimethylarginine may be an endogenous proatherogenic molecule.

146 ne expression and drives the accumulation of proatherogenic myeloid cells in atherosclerotic aortas.

147 solated from 38 subjects were categorized as proatherogenic or antiatherogenic according to their cap

148 RF-1 or miR-126 expression recapitulated the proatherogenic or antiatherogenic regulation of VCAM-1.

149 protein-associated phospholipase A2, plays a proatherogenic or antiatherogenic role in atherosclerosi

150 t, they suggest a rather complex one, either proatherogenic or antiatherogenic, depending on the cell

151 Proatherogenic oxidized low-density lipoprotein (oxLDL)

152 (LDL) by cells in the artery wall leads to a proatherogenic particle that may help initiate early les

153 oxidized phospholipids to yield potentially proatherogenic particles, have been associated with CHD

154 rom vitamin D-deficient subjects will have a proatherogenic phenotype compared with vitamin D-suffici

155 induced conversion of blood monocytes into a proatherogenic phenotype.

156 TNF-alpha is a master regulator of vascular proatherogenic phenotypic changes, and it has been linke

157 In addition to the proatherogenic phenotypic switching in areas of low ESS,

158 and outer adventitial vasa vasorum, deposit proatherogenic plasma molecules, recruit immune cells an

159 atelet activation promotes prothrombotic and proatherogenic platelet/leukocyte aggregate formation.

160 apoA1 levels may serve as a way to monitor a proatherogenic process in the artery wall.

161 didate genes could be classified to distinct proatherogenic processes, including lipid metabolism and

162 in lipoprotein oxidation and other potential proatherogenic processes.

163 ovel chlorinated oxidized lipid species with proatherogenic properties in vivo has not yet been repor

164 cholesterol metabolism may contribute to the proatherogenic properties of LPS.

165 The proatherogenic properties of the cholesterol 5,6-secoste

166 maintenance of a stable HDL pool, and other proatherogenic properties such as decreasing clearance o

167 s and unsaturated lysophospholipids, possess proatherogenic properties, as shown by induction of P-se

168 studies indicate that CRP might have direct proatherogenic properties.

169 atherosclerotic development and that SPT has proatherogenic properties.

170 The proatherogenic property of Lp(a) can be attributed in pa

171 hrombospondin-1, a potent antiangiogenic and proatherogenic protein involved in development of diabet

172 of STAT3 that controls the expression of the proatherogenic protein profilin-1 in response to 7-ketoc

173 TSP-1 is a potent antiangiogenic and proatherogenic protein that may represent an important l

174 ondin-1 (TSP-1), a potent antiangiogenic and proatherogenic protein, has been implicated in the devel

175 We identified TREM-1 as a major upstream proatherogenic receptor.

176 diabetic db/db mice would exhibit increased proatherogenic responses relative to those from control

177 view, therapeutic strategies that target the proatherogenic responses to retained lipoproteins and th

178 ed enhanced inflammatory gene expression and proatherogenic responses.

179 al cells, caveolin-1 and caveolae may play a proatherogenic role by promoting the transcytosis of LDL

180 These data document a proatherogenic role for CRP in vivo.

181 , providing genetic evidence in support of a proatherogenic role for macrophage cyclooxygenase-2 expr

182 Data support a proatherogenic role for oxidized LDL in atherosclerosis

183 This study supports a proatherogenic role for pDCs in murine atherosclerosis a

184 ints compared with BALB/c mice, supporting a proatherogenic role for Th1 response.

185 experiments, in-vivo studies that support a proatherogenic role of C-reactive protein are less likel

186 knowledge, the first in vivo evidence for a proatherogenic role of endothelial TRPC3.

187 Here, we investigate the proatherogenic role of NKT cells in an adoptive transfer

188 lipopolysaccharide or high-fat diet plays a proatherogenic role.

189 n the mRNA coding sequence of Apob and other proatherogenic secreted proteins, including apolipoprote

190 hepatic cholesterol and triglycerides, and a proatherogenic serum lipoprotein profile.

191 ine (TMA), which is further metabolized to a proatherogenic species, trimethylamine-N-oxide (TMAO).

192 e findings extend previous work indicating a proatherogenic state in healthy, nondiabetic subjects wh

193 a number of these processes, resulting in a proatherogenic state.

194 ort, impaired HDL as a marker and a cause of proatherogenic states, and experimental and current appr

195 ase in cholesteryl ester transfer (CET), the proatherogenic step in reverse-cholesterol transport tha

196 tion factor that can be activated by diverse proatherogenic stimuli such as inflammatory cytokines, l

197 cted antigen presentation by pDCs in driving proatherogenic T cell immunity.

198 hway has an important role in downregulating proatherogenic T cell response and atherosclerosis by li

199 test whether the PD-1/PD-L pathway regulates proatherogenic T cell responses, we compared atheroscler

200 of DC activation and hence the intensity of proatherogenic T cell responses.

201 as associated with significant reductions of proatherogenic T cell-derived interferon-gamma and lesio

202 protective Treg response trumps the loss of proatherogenic T effector cell activation.

203 reduced TFH abundance and suppression of the proatherogenic TFH response.

204 Proatherogenic TGRL increased expression of VCAM-1, inte

205 uction also facilitates nuclear transport of proatherogenic transcription factors, increases transcri

206 , such as isoprostanes, could still induce a proatherogenic vascular phenotype.

207 -33-based therapies because they might raise proatherogenic VLDL-TAG levels.

208 ptake of modified lipoproteins is considered proatherogenic, we found that IL10 also increases choles

209 PCSK9 overexpression is proatherogenic, whereas its absence is protective.

210 cell subsets identified the Th1 responses as proatherogenic, whereas regulatory T-cell responses exer